Tetragon Partners GP Ltd reported 31 positions worth $607.65M for the quarter ended Jun 30, 2026, up 26.6% on the prior quarter. It opened 5 new positions, added to 15, trimmed 4 and exited 6. Its largest holding is UiPath, Inc. at 55.4% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| PATH UiPath, Inc. | +5.74M | +22.8% | $62.42M | 55.36% |
| ALKT Alkami Technology, Inc. | +600.3K | – | $10.88M | 1.79% |
| RLAY Relay Therapeutics, Inc. | +388.8K | +214.1% | $7.27M | 1.76% |
| CELC Celcuity Inc. | +64.1K | – | $6.71M | 1.1% |
| IONS Ionis Pharmaceuticals Inc | +55.4K | +132.7% | $4.39M | 1.27% |
| DFTX Definium Therapeutics, Inc. | +87.0K | +43.5% | $4.09M | 2.22% |
| MBX MBX Biosciences, Inc. | +58.1K | +39.9% | $3.21M | 1.85% |
| HRMY Harmony Biosciences Holdings, Inc. | +81.7K | +68.5% | $2.97M | 1.2% |
| CUE Cue Biopharma, Inc. | +93.8K | – | $2.96M | 0.487% |
| PHVS Pharvaris N.V. | +74.0K | +33.4% | $2.56M | 1.68% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| PRAX Praxis Precision Medicines, Inc. | -16.0K | -100.0% | $5.14M | Exited |
| AXSM Axsome Therapeutics, Inc. | -20.1K | -100.0% | $3.39M | Exited |
| MPLT MapLight Therapeutics, Inc. | -112.1K | -100.0% | $2.28M | Exited |
| AARD Aardvark Therapeutics, Inc. | -316.6K | -100.0% | $1.19M | Exited |
| NKTR Nektar Therapeutics | -16.0K | -15.6% | $1.12M | 0.999% |
| RARE Ultragenyx Pharmaceutical Inc. | -39.5K | -100.0% | $826.96K | Exited |
| CLDX Celldex Therapeutics, Inc. | -21.9K | -7.0% | $813.97K | 1.78% |
| AMLX Amylyx Pharmaceuticals, Inc. | -20.0K | -6.3% | $358.32K | 0.881% |
| KPTI Karyopharm Therapeutics Inc. | -53.0K | -100.0% | $295.12K | Exited |
| ANNX Annexon, Inc. | -50.0K | -3.9% | $285.50K | 1.17% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| PRAX Praxis Precision Medicines, Inc. | -16.0K | $5.14M | 1.07% |
| AXSM Axsome Therapeutics, Inc. | -20.1K | $3.39M | 0.706% |
| MPLT MapLight Therapeutics, Inc. | -112.1K | $2.28M | 0.475% |
| AARD Aardvark Therapeutics, Inc. | -316.6K | $1.19M | 0.249% |
| RARE Ultragenyx Pharmaceutical Inc. | -39.5K | $826.96K | 0.172% |
| KPTI Karyopharm Therapeutics Inc. | -53.0K | $295.12K | 0.061% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | PATH UiPath, Inc. | Technology | 30.95M | $336.43M | 55.36% | +5.74M | +22.8% | Added | 6.79% |
| 2 | KGEI Kolibri Global Energy Inc. | Energy | 6.83M | $33.85M | 5.57% | 0 | 0.0% | Unchanged | 19.27% |
| 3 | AUTL Autolus Therapeutics plc | Healthcare | 9.50M | $15.20M | 2.5% | 0 | 0.0% | Unchanged | 3.57% |
| 4 | LYFT Lyft, Inc. | Technology | 1.00M | $14.61M | 2.4% | 0 | 0.0% | Unchanged | 0.26% |
| 5 | DFTX Definium Therapeutics, Inc. | Healthcare | 287.0K | $13.50M | 2.22% | +87.0K | +43.5% | Added | 0.21% |
| 6 | WK Workiva Inc | Technology | 250.0K | $12.13M | 2% | 0 | 0.0% | Unchanged | 0.45% |
| 7 | CXM Sprinklr, Inc. | Technology | 2.20M | $11.35M | 1.87% | 0 | 0.0% | Unchanged | 0.91% |
| 8 | MBX MBX Biosciences, Inc. | Healthcare | 203.5K | $11.24M | 1.85% | +58.1K | +39.9% | Added | 0.42% |
| 9 | ALKT Alkami Technology, Inc. | Technology | 600.3K | $10.88M | 1.79% | +600.3K | – | New | 0.56% |
| 10 | CLDX Celldex Therapeutics, Inc. | Healthcare | 290.4K | $10.81M | 1.78% | -21.9K | -7.0% | Reduced | 0.37% |
| 11 | RLAY Relay Therapeutics, Inc. | Healthcare | 570.3K | $10.67M | 1.76% | +388.8K | +214.1% | Added | 0.26% |
| 12 | ARWR Arrowhead Pharmaceuticals, Inc. | Healthcare | 130.5K | $10.64M | 1.75% | +3,286 | +2.6% | Added | 0.09% |
| 13 | PHVS Pharvaris N.V. | Healthcare | 295.6K | $10.22M | 1.68% | +74.0K | +33.4% | Added | 0.5% |
| 14 | ALKS Alkermes plc. | Healthcare | 190.0K | $9.95M | 1.64% | +30.2K | +18.9% | Added | 0.11% |
| 15 | IMVT Immunovant, Inc. | Healthcare | 255.9K | $9.86M | 1.62% | +37.4K | +17.1% | Added | 0.12% |
Tip. Select a row to see that position’s full history at Tetragon Partners GP.
As of its Q2 2026 13F filing, Tetragon Partners GP Ltd’s five largest positions were UiPath, Inc. (PATH) at 55.4%, Kolibri Global Energy Inc. (KGEI) at 5.6%, Autolus Therapeutics plc (AUTL) at 2.5%, Lyft, Inc. (LYFT) at 2.4%, Definium Therapeutics, Inc. (DFTX) at 2.2% of the reported portfolio.
Tetragon Partners GP Ltd reported a 13F portfolio worth $607.65M across 31 positions for Q2 2026. That is up 26.6% from the previous quarter.
Its largest purchases by value were UiPath, Inc. ($62.42M), Alkami Technology, Inc. ($10.88M), Relay Therapeutics, Inc. ($7.27M). It opened 5 new positions.
Its largest sales by value were Praxis Precision Medicines, Inc. ($5.14M), Axsome Therapeutics, Inc. ($3.39M), MapLight Therapeutics, Inc. ($2.28M). It exited 6 positions entirely.
From the Form 13F-HR reports Tetragon Partners GP Ltd files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.